Atara Biotherapeutics Announces Executive Departures

Oct 25, 2019 6:11pm EDT

Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

Sep 09, 2019 8:00am EDT

Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference

Aug 28, 2019 4:05pm EDT

Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress

Aug 08, 2019 7:30am EDT

Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019

Aug 01, 2019 4:00pm EDT

Atara Biotherapeutics Announces Pricing of $150.0 Million Public Offering

Jul 18, 2019 11:52pm EDT

Atara Biotherapeutics Announces Proposed Offering of Common Stock

Jul 18, 2019 4:01pm EDT

Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year

Jul 16, 2019 7:00am EDT

Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN)

Jun 29, 2019 7:00am EDT

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 25, 2019 4:05pm EDT